Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:51:34 2024-06-25 EDT			5-day change	1st Jan Change
0.1322 ^USD	+12.65%		+58.89%	-9.08%

06-07	Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer	CI
06-06	Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index	CI

Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer

June 07, 2024 at 07:02 am

On June 4, 2024, Galera Therapeutics, Inc. notified Robert A. Beardsley, Ph.D., the Company?s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics.

Latest news about Galera Therapeutics, Inc.

Galera Therapeutics, Inc. Eliminates Robert A. Beardsley as Chief Operating Officer	06-07	CI
Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from S&P TMI Index	06-05	CI
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	06-03	MT
Top Premarket Decliners	06-03	MT
Galera Therapeutics, Inc.(OTCPK:GRTX) dropped from NASDAQ Composite Index	06-02	CI
Galera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Galera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Galera Therapeutics Announces Review of Strategic Alternatives	23-10-31	CI
Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial	23-10-31	DJ
Galera Therapeutics, Inc. Announces Receipt of Type A Meeting Minutes and Strategic Update	23-10-31	CI
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy, Adjusts Price Target to $0.30 From $6	23-08-16	MT
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount	23-08-10	CI
Galera Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	23-08-10	CI
Galera Therapeutics, Inc. Announces Elimination of Mark Bachleda, Pharm.D., Chief Commercial Officer	23-08-10	CI
Piper Sandler Downgrades Galera Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.50 From $6	23-08-10	MT
Galera shares tank after US FDA declines to approve inflammation disease drug	23-08-09	RE
Stocks to Watch : Applovin, Disney, Galera Therapeutics	23-08-09	DJ

Chart Galera Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Companyâs lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Companyâs second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
GALERA THERAPEUTICS, INC.	-9.08%	7.19M
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	122B
REGENERON PHARMACEUTICALS, INC.	+21.96%	116B
ARGENX SE	+25.50%	27.03B
BIONTECH SE	-20.05%	20.36B
BEIGENE, LTD.	-16.28%	15.91B
GENMAB A/S	-15.85%	16.43B
WUXI APPTEC CO., LTD.	-44.35%	15.6B
SAREPTA THERAPEUTICS, INC.	+63.91%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.59B

Bio Therapeutic Drugs